Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis

Ruxolitinib cream is a topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor.

[1]  W. Begolka,et al.  33843 Atopic dermatitis polypharmacy and out-of-pocket health care expenses in the United States , 2022, Journal of the American Academy of Dermatology.

[2]  S. Kwatra,et al.  Itch: pathogenesis and treatment. , 2021, Journal of the American Academy of Dermatology.

[3]  S. Kwatra,et al.  Itch: epidemiology, clinical presentation, and diagnostic workup. , 2021, Journal of the American Academy of Dermatology.

[4]  Xinzhong Dong,et al.  Transcriptomic analysis of atopic dermatitis in African Americans is characterized by Th2/Th17-centered cutaneous immune activation , 2021, Scientific Reports.

[5]  A. Paller,et al.  Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials , 2021, The Lancet.

[6]  Xuejun Chen,et al.  Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies , 2021, American Journal of Clinical Dermatology.

[7]  S. Kwatra,et al.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses , 2021, Drugs.

[8]  M. Dibonaventura,et al.  Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey Analysis , 2021, Advances in Therapy.

[9]  J. Piercy,et al.  Extent and Impact of Inadequate Disease Control in US Adults with a History of Moderate to Severe Atopic Dermatitis Following Introduction of New Treatments , 2021, Dermatology and Therapy.

[10]  S. Kwatra,et al.  Janus kinase inhibitors for atopic dermatitis: a promising treatment modality , 2021, Clinical and experimental dermatology.

[11]  J. Silverberg,et al.  Financial Burden of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States , 2020, Dermatitis : contact, atopic, occupational, drug.

[12]  T. Luger,et al.  The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey , 2020, Dermatology and Therapy.

[13]  S. Kwatra,et al.  Sleep disturbance in adults with chronic pruritic dermatoses is associated with increased C-reactive protein levels. , 2020, Journal of the American Academy of Dermatology.

[14]  F. Wang,et al.  Itch: A Paradigm of Neuroimmune Crosstalk. , 2020, Immunity.

[15]  Winfred Frazier,et al.  Atopic Dermatitis: Diagnosis and Treatment. , 2020, American family physician.

[16]  J. Silverberg,et al.  Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS. , 2020, Journal of the American Academy of Dermatology.

[17]  Shannon L. Russell,et al.  Insights From Caregivers on the Impact of Pediatric Atopic Dermatitis on Families: "I'm Tired, Overwhelmed, and Feel Like I'm Failing as a Mother". , 2020, Dermatitis : contact, atopic, occupational, drug.

[18]  H. Nakagawa,et al.  Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. , 2020, Journal of the American Academy of Dermatology.

[19]  M. Howell,et al.  Targeting the Janus Kinase Family in Autoimmune Skin Diseases , 2019, Front. Immunol..

[20]  M. Ardeleanu,et al.  Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis† , 2019, The British journal of dermatology.

[21]  J. Szepietowski,et al.  Influence of Itch and Pain on Sleep Quality in Atopic Dermatitis and Psoriasis. , 2019, Acta dermato-venereologica.

[22]  D. Margolis,et al.  Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[23]  M. Lebwohl,et al.  Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor. , 2018, Acta dermato-venereologica.

[24]  K. Sayaseng,et al.  Pathophysiology and Management of Mild to Moderate Pediatric Atopic Dermatitis. , 2018, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[25]  J. Piercy,et al.  Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis , 2017, The Journal of dermatology.

[26]  Jonathan R. Brestoff,et al.  Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch , 2017, Cell.

[27]  S. Ständer,et al.  Itch Assessment with Visual Analogue Scale and Numerical Rating Scale: Determination of Minimal Clinically Important Difference in Chronic Itch. , 2016, Acta dermato-venereologica.

[28]  M. Lebwohl,et al.  Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. , 2016, Journal of the American Academy of Dermatology.

[29]  A. Kimball,et al.  Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.

[30]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. , 2014, Journal of the American Academy of Dermatology.

[31]  L. Chan,et al.  The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis , 2013, JAK-STAT.

[32]  J. Szepietowski,et al.  Relationship between itch and psychological status of patients with atopic dermatitis , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[33]  H. Kantarjian,et al.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.

[34]  V. Ho,et al.  A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids , 2007, The British journal of dermatology.

[35]  Torsten Zuberbier,et al.  Patient perspectives on the management of atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[36]  Erika Sevetson,et al.  The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. , 2017, The Journal of investigative dermatology.

[37]  J. Silverberg,et al.  Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. , 2015, The Journal of investigative dermatology.

[38]  J. Ring,et al.  Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. , 1997, Dermatology.

[39]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.